Notable examples include drugs like imatinib (Gleevec), which targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML), and erlotinib (Tarceva), acts on the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.